Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Consortium to Develop MicroRNA-Based Drugs for Treatment of Head and Neck Cancer

By BiotechDaily International staff writers
Posted on 28 Nov 2013
A consortium of biotechnology companies and medical centers from The Netherlands, Germany, and Israel has been granted funding from the European Union’s FP7 program to develop a new class of highly selective targeted therapeutics for the treatment of head and neck cancer based on novel tumor-selective lethal micro RNAs (miRNAs).

Head and neck cancer is the sixth most common cancer worldwide, and since patients with this type of cancer often present with advanced stages of disease, the five-year survival rate is less than 60%.

miRNAs are snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. Considerable effort is going into development of clinical therapeutic applications for miRNAs.

The new project, which is known by the acronym MiRacle, brings together the biopharmaceutical companies InteRNA Technologies BV (Nijmegen, The Netherlands); Quiet Therapeutics (Ness Ziona, Israel); BioSpring (Frankfurt, Germany); OctoPlus (Leiden, The Netherlands); and LPT (Hamburg, German) and the Dutch medical center, VU University Medical Center (Amsterdam, The Netherlands).

The MiRacle consortium, which has been awarded an SME (small manufacturing entity) grant of about 1.2 million euros, will call upon its members for synthesis of biochemically active miRNAs, expertise in drug formulation for the specific delivery of therapeutic miRNA into humans, understanding of synthesis of complex drug formulations, preclinical testing, and conducting of toxicity tests that are required for RNA based drug registration.

Roel Schaapveld, CEO of InteRNA Technologies, said, “The unique tumor-selective lethal miRNAs identified display a very interesting biology and potential therapeutic effect that warrants further development towards the clinic. This FP7 grant exemplifies that with this consortium we have all the expertise in place to bring a tumor killing miRNA in a targeted and safe manner towards registration for first in human testing.”

“This FP7 grant enables the next step in the translation of the tumor-selective lethal microRNAs that we discovered,” said Dr. Ruud Brakenhof, professor of cancer genetics at VU University Medical Center.

Related Links:

InteRNA Technologies BV
Quiet Therapeutics
OctoPlus



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.